Literature DB >> 24625824

The COPD pipeline.

Yasser Mushtaq1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24625824     DOI: 10.1038/nrd4254

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

Authors:  Peter Kardos; Marion Wencker; Thomas Glaab; Claus Vogelmeier
Journal:  Am J Respir Crit Care Med       Date:  2006-10-19       Impact factor: 21.405

2.  Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Authors:  Lui G Franciosi; Zuzana Diamant; Katharine H Banner; Rob Zuiker; Nicoletta Morelli; Ingrid M C Kamerling; Marieke L de Kam; Jacobus Burggraaf; Adam F Cohen; Mario Cazzola; Luigino Calzetta; Dave Singh; Domenico Spina; Michael J A Walker; Clive P Page
Journal:  Lancet Respir Med       Date:  2013-10-25       Impact factor: 30.700

  2 in total
  6 in total

1.  Effects of the novel BK (KCa 1.1) channel opener GoSlo-SR-5-130 are dependent on the presence of BKβ subunits.

Authors:  R J Large; A Kshatri; T I Webb; S Roy; A Akande; E Bradley; G P Sergeant; K D Thornbury; N G McHale; M A Hollywood
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

2.  The COPD Pipeline, XXVI.

Authors:  Nicholas Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2015-01-16

3.  The COPD Pipeline XXIX.

Authors:  Nicholas Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2015-10-20

4.  The COPD Pipeline, XXV.

Authors:  Nicholas Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 5.  Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease.

Authors:  Dhruv R Seshadri; Anand Ramamurthi
Journal:  Front Pharmacol       Date:  2018-07-16       Impact factor: 5.810

6.  Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model.

Authors:  Adam Bohr; Nicolas Tsapis; Camilla Foged; Ilaria Andreana; Mingshi Yang; Elias Fattal
Journal:  Eur J Pharm Biopharm       Date:  2020-08-13       Impact factor: 5.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.